RealFeedApp beta
Ageing and longevity
Aging and longevity: how aging works, geroprotectors and research on extending healthy life.
- Impaired removal of senescence cells due to aging
The study found that age-related decline in chaperone-mediated autophagy impairs the clearance of senescence cells. The article also reviews differences identified in gut microbiome composition between young, old, and older adults.
- Study of 108 HIV participants confirms semaglutide effect
A study of 108 adults with HIV found that semaglutide injections slowed the accumulation of epigenetic clocks in DNA. Results were published in Nature Communications.
- Income and education influence life expectancy
The study applies mediation analysis to determine how much lifestyle factors explain the correlation between socioeconomic status and longevity.
- p<0.001 in the left hippocampus
A post-hoc analysis of the CLEAR MIND trial on 49 participants showed Lomecel-B slowed neuroinflammation in the hippocampus and temporal/parietal cortex.
- Smooth muscle loses ability to constrict and relax
Vascular aging is the primary cause of human mortality, leading to atherosclerosis and vessel rupture. The vascular network loses capillary density and smooth muscle function, increasing risks of heart attacks and strokes.
- Inhibiting microRNA stimulates muscle growth in aged mice
Researchers from Elenae Therapeutics demonstrated that inhibiting microRNA miR-128-3p promotes muscle growth in aged mice, offering a new strategy to counteract age-related muscle loss.
- U.S. Patent No. 12,759,979 expires in 2045
The patent protects a novel crystalline form of zervimesine for treating Alzheimer's and dementia with Lewy bodies. The drug is currently in Phase 2 clinical trials.
- Sava Technologies raised 68 million dollars in total funding
London-based Sava Technologies raised $36 million in Series B from Ascensia Diabetes Care to commercialize its subcutaneous glucose sensor. A European launch is scheduled for 18 to 24 months after obtaining CE approval.
- Senescent cells accumulate in later life
While the immune system clears senescent cells efficiently in youth, this clearance mechanism falters in later life, allowing these cells to accumulate.
- Snowplow clears driveway until dawn
New research identifies fat infiltration in muscle tissue as a biomarker of aging, driven by reduced cardiolipin levels and mitochondrial dysfunction.
- Accrua platform launches in the US in October 2026
Accrua by Deep Longevity uses an AI model to identify 'fast agers' via blood tests and directs them to GLP-1 treatments. The US telehealth platform is scheduled to launch in October 2026.
- Researchers found a link between GLP-1 and biological age
Findings from Eli Lilly and Novo Nordisk show that overweight and diabetic patients using GLP-1s have a biological age two to three years younger than placebo users.
- Two of three glaucoma patients showed early visual-field signals
The Phase 1 trial of ER-100, which activates Yamanaka factors in the eye, did not cause serious adverse events in three participants. Early visual field signals were observed in two of the three patients with open-angle glaucoma.
- Bolotana is home to 10 centenarians
Researchers verified that ten residents of Bolotana reached the age of 100 despite the village having no gym. The centenarian rate there is roughly 10 times higher than the US average.
- Jonathan's genome contains 287 unique gene variants
Researchers identified 287 unique gene variants that keep epigenetic switches regulating DNA repair and metabolism active. This prevents the accumulation of genetic wear and tear typically seen in aging Aldabrachelys gigantea.
- Jonathan, 194 years old, lives on Saint Helena
Scientists sequenced the genome of Jonathan, a tortoise born in 1832 and now approximately 194 years old. The study helps reveal the secrets behind her extreme lifespan.
- Novo and Lilly present early longevity data
Novo Nordisk and Eli Lilly presented data showing reduced mortality and improved physical function in a cohort of 19,117 participants from the SELECT trial.
- Do not view mTOR as a single pharmaceutical target
The study found that blocking PD-L1 in the brain restores glial cell function. Researchers advise not viewing mTOR as a single pharmaceutical target because context matters.
